Recon: Trump admin eyes term limits on top health jobs; Pfizer temporarily reduces vaccine shipments

• Vaccine reserve was already exhausted when Trum administration vowed to release it (Washington Post)
• Trump admin races to enact term limits for top health scientists (Politico)
• Trump wants billions cut from global Covid vaccine distributor (Politico)
• Former FDA commissioner: "Reliable drug supply is absolutely critical" (Axios)
• Biden taps D.C. veteran David Kessler to head Warp Speed (Politico) (STAT) (NYTimes)
• Researchers test common drugs in quest for treatments for early COVID-19 (Boston Globe)
• Moderna looks to test Covid-19 booster shots a year after initial vaccination (CNBC)
• Moderna struggles to find 3,000 adolescent volunteers needed for COVID-19 vaccine trial (USA Today)
• Trump administration will let nearly all doctors prescribe addiction medicine buprenorphine (STAT)
• 'We Cannot Afford Inaction': Biden Unveils $1.9 Trillion COVID-19 Relief Plan (NPR)
• Biden to unveil coronavirus vaccine distribution plan as cases soar (Reuters)
• U.S. health officials push hospitals to administer unused Covid antibody drugs (CNBC)

• World is in a race with a coronavirus trying to mutate, WHO says (Reuters)
• WHO stops short of advising proof of COVID shots for travel (Reuters)
• Pfizer to Cut Vaccine Shipments as Belgian Factory Renovated (Bloomberg) (Reuters 1, 2, 3) (FT)
• Pfizer has told EU it can still make vaccine deliveries in 1st qtr, Von der Leyen says (Reuters)
• Pfizer vaccine delay comes as Canada battles surge in COVID-19 (Reuters)
• EMA chief hopes J&J will seek COVID-19 vaccine approval next month (Reuters)
• Brazil regulator says documents still missing for fast-track COVID-19 vaccine approval (Reuters 1, 2)
• China's Sinopharm COVID-19 vaccine safe for children, teenagers: state media (Reuters)
• International COVID-19 vaccine poll shows higher mistrust of Russia, China shots (Reuters)
• AstraZeneca lung cancer drug gets nod for new dosing regimen in EU, UK (Reuters)

• China allows entry to WHO COVID-19 probe member after negative test (Reuters)
• CVS and Walgreens Under Fire for Slow Pace of Vaccination in Nursing Homes (KHN)
• UK regulator refuses to approve mass COVID-19 testing at England schools - The Guardian (Reuters)
• New coronavirus variant could become dominant strain in March, CDC warns (STAT)
• Some big U.S. pharmacies will not check ID before administering COVID-19 vaccines (Reuters)
• Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response (STAT)
• Paraguay approves emergency use of Sputnik vaccine, Russian sovereign wealth fund says (Reuters)
• Azerbaijan to begin vaccinations next week, to use Chinese shot: govt (Reuters)

• Biopharma dealmaking in 2020 (Nature)
• 2020 FDA approvals: momentum kept despite COVID-19, but value falls (Nature)
• FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (FDA)
• Janet Woodcock is in the running for FDA commissioner — what does that mean for the agency's future? (Endpoints)
• Aurinia in ‘show-me phase’ as FDA nears approval decision on autoimmune kidney disease drug (STAT)
• Gilead partner Arcus earns analysts' plaudits for early pancreatic cancer data that 'exceeded expectations' (Endpoints)
• Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO (CNBC)
• Cognate doubles manufacturing capacities in Memphis, Europe, as demand for cell and gene therapies skyrockets (Endpoints)
• Amgen strikes $240m autoimmune deal with Evoq Therapeutics (PMLive)
• Looking to build in red-hot viral vector space, Thermo Fisher inks $878M deal for Belgian manufacturer's 2 plants (Endpoints)
• NICE recommends GSK's ZEJULA for advanced ovarian cancer (Pharmafile)
• Landos Biopharma guns for a $100 million IPO to boost AI autoimmune R&D work (Fierce)
• Fujifilm continues CMDO expansion spree with $76M in funding for new Boston site (Fierce)
• JPM: Jazz eyes a 'dramatic' shift to new-drug revenue by 2022, CEO says (Fierce)
• JPM: Established relationships were key to pandemic drug launches, Incyte CEO says (Fierce)
• CEVEC Inks AAV Manufacturing Deal with Biogen (GEN)
• Recipharm Signs Manufacturing Agreement with Sweden’s Enzymatica (GEN)
• Cytiva Delivers Modular Biologics Factory to Lonza (GEN)
• Genmab Set for Stand-Alone Drug Development, Biz in Japan (PharmaJapan)
• MHLW Initiates Discussions on Amendment of Clinical Research Law (PharmaJapan)

• Abbott, Quidel tout big COVID-19 testing year despite vaccine rollout: JPM21 (MedtechDive)
• Remote monitoring, wearable companies look to capitalize on virtual care boom: JPM21 (MedtechDive)
• UK Medtechs Determined To Exploit Digital Health Opportunity Born From The Pandemic (MedtechInsight)

• Insulin Report Revives Senate Finance Committee Push On Drug Pricing Legislation (Pink Sheet) (Law360)
• Medicaid: Data Completeness and Accuracy Have Improved, Though Not All Standards Have Been Met (GAO)
• Medicare Part D spent twice what the VA paid for the same drugs (STAT)
• 6th Circ. Won't Stop Ex-FDA Chief's Opioid MDL Testimony (Law360)
• Mallinckrodt Ch. 11 Talks Stalled Amid Fee Row, Judge Told (Law360)